Entrada Therapeutics, Inc. Common Stock
TRDAEntrada Therapeutics, Inc. is a biotechnology company focused on developing intracellular biologic therapies. Utilizing its proprietary platform, the company aims to create innovative treatments for diseases with high unmet medical needs by delivering therapeutic molecules directly into cells.
Company News
Questex's Fierce Biotech and Fierce Pharma announced the 2025 Life Sciences Innovation Awards, recognizing groundbreaking companies across various technological domains in healthcare and biotechnology.
5AM Venture Management sold its entire 189,593 share stake in Viking Therapeutics, representing a $5.02 million position change. The sale appears to be a portfolio rebalancing rather than a lack of confidence in the company's potential.
Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for ...
